Patents by Inventor Nathaniel Henning

Nathaniel Henning has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Small molecule inhibitors of SRC tyrosine kinase
    Patent number: 12365664
    Abstract: Disclosed herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof. Also disclosed herein are methods of using the compounds of Formula (I) in the treatment of certain diseases (e.g., cancer).
    Type: Grant
    Filed: June 18, 2020
    Date of Patent: July 22, 2025
    Assignees: Dana-Farber Cancer Institute, Inc., Board of Regents of the University of Texas System
    Inventors: Nathanael S. Gray, Guangyan Du, Tinghu Zhang, Nathaniel Henning, Suman Rao, Kenneth Westover, Deepak Gurbani
  • Degraders that target proteins via KEAP1
    Patent number: 12365677
    Abstract: Disclosed are bifunctional compounds, pharmaceutical compositions containing them, and methods of making and using them to treat diseases and disorders characterized by aberrant protein activity wherein the protein is targeted for degradation by KEAP1 and the Cul3-based E3-ubiquitin ligase complex.
    Type: Grant
    Filed: July 18, 2019
    Date of Patent: July 22, 2025
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Nathanael S. Gray, Tinghu Zhang, Eric Fischer, Guangyan Du, Nozhat Safaee, Nathaniel Henning, Katherine Donovan
  • FEM1B PROTEIN BINDING AGENTS AND USES THEREOF
    Publication number: 20230148299
    Abstract: Disclosed herein, inter alia, are compounds for binding FEMIB protein and uses thereof. In an aspect, provided input pulldown herein is a pharmaceutical composition including a compound as described herein and a pharmaceutically acceptable excipient.
    Type: Application
    Filed: March 8, 2021
    Publication date: May 11, 2023
    Inventors: Michael Rape, Daniel K. Nomura, Nathaniel Henning, Andrew Manford
  • SMALL MOLECULE INHIBITORS OF SRC TYROSINE KINASE
    Publication number: 20220267294
    Abstract: Disclosed herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof. Also disclosed herein are methods of using the compounds of Formula (I) in the treatment of certain diseases (e.g., cancer).
    Type: Application
    Filed: June 18, 2020
    Publication date: August 25, 2022
    Inventors: Nathanael S. Gray, Guangyan Du, Tinghu Zhang, Nathaniel Henning, Suman Rao, Kenneth Westover, Deepak Gurbani
  • DEGRADERS OF FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2)
    Publication number: 20220175722
    Abstract: The present invention relates to bispecific compounds, compositions, and methods for treating diseases or conditions characterized or mediated by aberrant fibroblast growth factor receptor 2 (FGFR2) activity.
    Type: Application
    Filed: April 9, 2020
    Publication date: June 9, 2022
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Nathanael Gray, Tinghu Zhang, Guangyan Du, Nathaniel Henning, Jie Jiang
  • DEGRADERS OF KELCH-LIKE ECH-ASSOCIATED PROTEIN 1 (KEAP1)
    Publication number: 20220177466
    Abstract: The present invention relates to bifunctional compounds, compositions, and methods for treating diseases or conditions mediated by Kelch-like ECH-associated protein 1 (KEAP1). In some aspects, the present invention is directed to methods of treating diseases or disorders involving dysfunctional (e.g., dysregulated) KEAP1 activity, that entails administration of a therapeutically effective amount of a bifunctional compound of formula I or a pharmaceutically acceptable salt or stereoisomer thereof, to a subject in need thereof.
    Type: Application
    Filed: April 7, 2020
    Publication date: June 9, 2022
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Nathanael Gray, Tinghu Zhang, Guangyan Du, Nathaniel Henning, Jie Jiang, Eric Fischer, Katherine Donovan
  • DEGRADERS THAT TARGET PROTEINS VIA KEAP1
    Publication number: 20210276996
    Abstract: Disclosed are bifunctional compounds, pharmaceutical compositions containing them, and methods of making and using them to treat diseases and disorders characterized by aberrant protein activity wherein the protein is targeted for degradation by KEAP1 and the Cul3-based E3-ubiquitin ligase complex.
    Type: Application
    Filed: July 18, 2019
    Publication date: September 9, 2021
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Nathanael S. Gray, Tinghu Zhang, Eric Fischer, Guangyan Du, Nozhat Safaee, Nathaniel Henning, Katherine Donovan